ACE-031, at a strength of 1mg, is now generating significant interest across European markets. Early clinical studies in countries such as the Federal Republic of Germany, France, and the Great Britain have revealed positive results in treating certain nervous system ailments. Regulatory authorities across the continent are thoroughly reviewing the